- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06145555
Akutt psykologisk søvnstabilisering for pasienter innlagt på sykehus med depresjon
Disturbed sleep occurs in almost all patients in psychiatric inpatient care, and although it is well known that comorbid sleep disorders in depression often persist after treatment of depression and also increase the risk of new depressive episodes, the availability of effective, evidence-based treatments for sleep disorders in hospitalised patients is very limited.
The overall goal of the current project is to translate, adapt and evaluate an acute psychological sleep treatment based on cognitive behavioural therapy for insomnia (CBT-I) for patients hospitalized with depression and comorbid sleep problems in the specialized psychiatric inpatient care in the Stockholm Region. The main hypothesis for the study is that acute psychological sleep stabilization (APS) reduces self-reported sleep complains compared to care as usual reinforced with sleep hygiene advice, and secondary hypotheses are that APS also leads to reduced depressive symptoms and earlier discharge.
The project includes a pilot study, which will be followed by a randomized, controlled trial of APS compared to care as usual with structured sleep hygiene (minimal active control) and treatment effect is evaluated every three days during the hospital stay and 1,2,4 and 12 weeks after randomization. APS will be performed by existing staff in the department with the support of a psychologist.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Stockholm, Sverige
- Psykiatri Sydväst, Karolinska Hospital Huddinge
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Admitted to the psychiatric inpatient care (Psykiatri Sydväst)
- Depressive symptoms / confirmed depressive episode (uni- or bipolar)
- Reports or is observed to have sleep problems in the form of insomnia, hypersomnia or delayed circadian phase
- Knowledge of Swedish or English that is deemed sufficient to undergo the treatment
- Consent to be included in the study and is judged to have understood what the study entails (care according to the Compulsory Psychiatric Care Act is not in itself an exclusion criterion)
Exclusion Criteria:
- Dementia
- Intellectual disability
- Severe somatic comorbidity with life expectancy <6 months
- Ongoing mania / mixed-state
- Complex problems that make APS impossible or inappropriate
- Expected discharge within 3 days
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Acute psychological sleep stabilization
The basis of the treatment is CBT-I adapted to a short version performed by trained staff (nurses or mental health care assistants) together with a psychologist. The manuals are designed to be read by patients and staff together and each treatment manual covers a specific topic. The focus of the treatment is behavioral changes and central manuals are stimulus control and scheduled sleep and sleep compression (if needed). |
See above (arm description) |
|
Aktiv komparator: Sleep hygiene education
The control treatment is delivered through structured manuals which patients work through together with the staff. The manuals cover sleep hindering factors (eg coffee, nicotine), sleep promoting factors (eg physical activity during the day, relaxation, blinds), sleep aids (for example, weight blanket, calm music). |
See above (arm description) |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Insomnia Severity Index
Tidsramme: 2 weeks post randomization (secondary timepoints include day 4, 7, 10 and week 4 and 12)
|
A self-report measure of insomnia symptoms. 7-item, self-rated questionnaire measuring insomnia severity. Total score 0-28, higher score indicates more severe sleep problems. |
2 weeks post randomization (secondary timepoints include day 4, 7, 10 and week 4 and 12)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Patient Health Questionnaire (PHQ-9)
Tidsramme: Day 4, 7, 10 14 and week 4 and 12 post randomisation
|
Self-reported depressive symptoms. PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. Total score 0-27, higher score indicates more severe depressive symptoms. |
Day 4, 7, 10 14 and week 4 and 12 post randomisation
|
|
Generalised Anxiety Disorder 7-item scale (GAD-7)
Tidsramme: Day 4, 7, 10 14 and week 4 and 12 post randomisation
|
Self-reported anxiety symptoms. A seven-item instrument that is used to measure or assess the severity of generalised anxiety disorder/symptoms. Total score 0-27. Higher scores indicative of more severe problem. |
Day 4, 7, 10 14 and week 4 and 12 post randomisation
|
|
European Quality of Life 5 Dimensions scale (EQ-5D)
Tidsramme: Week 2, 4 and 12 post randomisation
|
Self-reported quality of life. An instrument which evaluates the generic quality of life developed in Europe and widely used. The scale comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. |
Week 2, 4 and 12 post randomisation
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sleep Diary
Tidsramme: 0-14 days post randomisation
|
Participants will report their bedtime, risetime, amount of sleep daily using a simplified version of a sleep diary. We will look at total sleep time, sleep efficiency, and timing of sleep. |
0-14 days post randomisation
|
|
Actigraphy
Tidsramme: 0-14 days post randomisation
|
An actigraph is placed on the participant's arm for 2 weeks. It measures participants' arm-movements. An algorithm can be used to estimate sleep from movement data.Data from actigraphs will be reported and analysed |
0-14 days post randomisation
|
|
Side effects of treatment
Tidsramme: Day 7 and 14 post randomisation
|
Patients will be asked to report any side-effects of the treatment with an open question |
Day 7 and 14 post randomisation
|
|
Treatment Credibility Scale
Tidsramme: Day 4 post randomisation
|
A five-item version of Credibility/Expectancy Questionnaire, total score ranging from 0-50. Higher scores indicative of higher credibility. |
Day 4 post randomisation
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Sandra Tamm, Karolinska Institutet
- Hovedetterforsker: Susanna Jernelöv, Karolinska Institutet
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Dnr 2023-02223-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual data will not be shared
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .